NZ629867A - Igg stimulated remyelination of peripheral nerves - Google Patents

Igg stimulated remyelination of peripheral nerves

Info

Publication number
NZ629867A
NZ629867A NZ629867A NZ62986713A NZ629867A NZ 629867 A NZ629867 A NZ 629867A NZ 629867 A NZ629867 A NZ 629867A NZ 62986713 A NZ62986713 A NZ 62986713A NZ 629867 A NZ629867 A NZ 629867A
Authority
NZ
New Zealand
Prior art keywords
neuropathy
effective amount
therapeutically effective
medicament
igg
Prior art date
Application number
NZ629867A
Other languages
English (en)
Inventor
Birgit Maria Reipert
Hans-Peter Schwarz
Patrick Kuery
Nevena Tzekova
Hans-Peter Hartung
Corinna Hermann
Hartmut Ehrlich
Sebastian Bunk
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of NZ629867A publication Critical patent/NZ629867A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NZ629867A 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves NZ629867A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Publications (1)

Publication Number Publication Date
NZ629867A true NZ629867A (en) 2016-09-30

Family

ID=47884569

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629867A NZ629867A (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Country Status (21)

Country Link
US (5) US8986670B2 (https=)
EP (2) EP3590960B1 (https=)
JP (3) JP6335800B2 (https=)
KR (3) KR102170615B1 (https=)
CN (4) CN107551269A (https=)
AR (2) AR090211A1 (https=)
AU (3) AU2013203088B2 (https=)
BR (1) BR112014021240A2 (https=)
DK (2) DK2820042T3 (https=)
EA (2) EA201892521A1 (https=)
ES (2) ES2755056T3 (https=)
FI (1) FI3590960T3 (https=)
HK (1) HK1248534A1 (https=)
IL (3) IL277103B2 (https=)
MX (2) MX369444B (https=)
NZ (1) NZ629867A (https=)
PL (2) PL2820042T3 (https=)
PT (2) PT3590960T (https=)
SG (1) SG11201405302WA (https=)
TW (3) TWI700297B (https=)
WO (1) WO2013130826A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107551269A (zh) * 2012-02-29 2018-01-09 百深公司 周围神经的IgG刺激髓鞘再生
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
EP3908256A4 (en) * 2019-01-07 2022-09-21 Mallinckrodt Ard IP Unlimited Company METHOD TO PROMOTE REMYELINATION
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
EP0124506B1 (de) 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
IL152738A0 (en) * 2000-05-10 2003-06-24 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
CA2514117A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
SG178744A1 (en) * 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
CN107551269A (zh) * 2012-02-29 2018-01-09 百深公司 周围神经的IgG刺激髓鞘再生

Also Published As

Publication number Publication date
BR112014021240A2 (pt) 2018-09-18
US8986670B2 (en) 2015-03-24
IL234303B (en) 2020-09-30
IL277103B1 (en) 2025-03-01
KR20220045087A (ko) 2022-04-12
JP6637934B2 (ja) 2020-01-29
JP2018030856A (ja) 2018-03-01
ES2755056T3 (es) 2020-04-21
PT3590960T (pt) 2023-04-18
US20210300997A1 (en) 2021-09-30
AR090211A1 (es) 2014-10-29
EA201892521A1 (ru) 2019-07-31
JP6335800B2 (ja) 2018-05-30
HK1206035A1 (en) 2015-12-31
US20130224150A1 (en) 2013-08-29
AU2016201137A1 (en) 2016-03-10
SG11201405302WA (en) 2014-09-26
US20150232536A1 (en) 2015-08-20
EP3590960A1 (en) 2020-01-08
IL274512A (en) 2020-06-30
EP2820042A2 (en) 2015-01-07
WO2013130826A3 (en) 2013-12-05
KR20200126005A (ko) 2020-11-05
CN109966488A (zh) 2019-07-05
TW201400502A (zh) 2014-01-01
KR102673154B1 (ko) 2024-06-05
HK1248534A1 (zh) 2018-10-19
PL2820042T3 (pl) 2020-03-31
IL274512B2 (en) 2024-07-01
TWI700297B (zh) 2020-08-01
EP3590960B1 (en) 2023-03-29
PT2820042T (pt) 2019-10-31
KR20140134690A (ko) 2014-11-24
IL274512B1 (en) 2024-03-01
JP6979990B2 (ja) 2021-12-15
CN104302666A (zh) 2015-01-21
CN107551269A (zh) 2018-01-09
AU2018200026B2 (en) 2019-12-05
AU2013203088B2 (en) 2015-12-03
JP2020059705A (ja) 2020-04-16
IL277103A (en) 2020-10-29
ES2943585T3 (es) 2023-06-14
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
MX2014010387A (es) 2015-09-25
TW201736398A (zh) 2017-10-16
AU2016201137B2 (en) 2017-10-12
MX369444B (es) 2019-11-08
TW201838654A (zh) 2018-11-01
AU2018200026A1 (en) 2018-01-25
WO2013130826A2 (en) 2013-09-06
US20180291087A1 (en) 2018-10-11
JP2015508824A (ja) 2015-03-23
US20200216518A1 (en) 2020-07-09
CN110343171A (zh) 2019-10-18
AR117207A2 (es) 2021-07-21
PL3590960T3 (pl) 2023-07-17
DK3590960T3 (da) 2023-04-24
DK2820042T3 (da) 2019-10-28
TWI632158B (zh) 2018-08-11
AU2013203088A1 (en) 2013-09-19
FI3590960T3 (fi) 2023-04-25
US10494418B2 (en) 2019-12-03
US9834593B2 (en) 2017-12-05
IL277103B2 (en) 2025-07-01
EA032000B1 (ru) 2019-03-29
MX2019012496A (es) 2020-01-20
EA201400966A1 (ru) 2014-12-30

Similar Documents

Publication Publication Date Title
NZ629867A (en) Igg stimulated remyelination of peripheral nerves
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
BR112013002211A2 (pt) 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-met
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
EA201201465A1 (ru) Лекарственные формы хинонов для лечения офтальмических заболеваний
BR112017003571A2 (pt) terapia combinada
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
IN2014DN09098A (https=)
UA117570C2 (uk) Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті
MY189505A (en) Methylene linked quinolinyl modulators of roryt
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201491857A1 (ru) АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ
BR112015022538A2 (pt) terapia de indução de rituximab seguida por terapia de acetato de glatirâmero
MX2015007183A (es) Metodos y composiciones para el tratamiento de mucopolisacaridosis tipo iiia administrado de forma intratecal.
NZ630864A (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
WO2012170918A3 (en) Methods of treatment for retinal diseases
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
EP3309555A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
TN2012000364A1 (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: BAXALTA GMBH, CH

Effective date: 20160414

Owner name: BAXALTA INC, US

Effective date: 20160414

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2018 BY COMPUTER PACKAGES INC

Effective date: 20170302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2019 BY ANAQUA SERVICES

Effective date: 20180122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2020 BY ANAQUA SERVICES

Effective date: 20190122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2021 BY ANAQUA SERVICES

Effective date: 20200121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2022 BY ANAQUA SERVICES

Effective date: 20210120

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2023 BY ANAQUA SERVICES

Effective date: 20220119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2024 BY ANAQUA SERVICES

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2025 BY ANAQUA SERVICES

Effective date: 20240124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2026 BY ANAQUA SERVICES

Effective date: 20250122